{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=GSK3640254+Capsule", "query": { "intervention": "GSK3640254 Capsule" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 8, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-02T20:06:35.836Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04900038", "title": "A Clinical Trial of GSK3640254 + Dolutegravir (DTG) in Human Immunodeficiency Virus-1 Infected Treatment-naive Adults", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "GSK3640254", "type": "DRUG" }, { "name": "Dolutegravir", "type": "DRUG" }, { "name": "Lamivudine capsules", "type": "DRUG" }, { "name": "Lamivudine tablets", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 85, "start_date": "2021-08-18", "completion_date": "2023-05-11", "has_results": true, "last_update_posted_date": "2023-12-14", "last_synced_at": "2026-09-02T20:06:35.836Z", "location_count": 8, "location_summary": "Bakersfield, California • Palm Springs, California • Denver, Colorado + 5 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Palm Springs", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Ft. Pierce", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04900038" }, { "nct_id": "NCT04425902", "title": "Evaluation of Pharmacokinetic Interaction Between GSK3640254 and Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "GSK3640254 200 mg", "type": "DRUG" }, { "name": "Caffeine 200 mg", "type": "DRUG" }, { "name": "Metoprolol 100 mg", "type": "DRUG" }, { "name": "Montelukast 10 mg", "type": "DRUG" }, { "name": "Flurbiprofen 100 mg", "type": "DRUG" }, { "name": "Omeprazole 40 mg", "type": "DRUG" }, { "name": "Midazolam 5 mg (2.5 mL)", "type": "DRUG" }, { "name": "Digoxin 0.25 mg", "type": "DRUG" }, { "name": "Pravastatin 40 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 20, "start_date": "2020-12-16", "completion_date": "2021-03-10", "has_results": true, "last_update_posted_date": "2024-01-05", "last_synced_at": "2026-09-02T20:06:35.836Z", "location_count": 1, "location_summary": "Las Vegas, Nevada", "locations": [ { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT04425902" }, { "nct_id": "NCT03816696", "title": "Study to Evaluate the Pharmacokinetic (PK) Interactions Between GSK3640254 and Dolutegravir (DTG)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "GSK3640254", "type": "DRUG" }, { "name": "DTG", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 16, "start_date": "2019-01-23", "completion_date": "2019-04-10", "has_results": true, "last_update_posted_date": "2020-03-19", "last_synced_at": "2026-09-02T20:06:35.836Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03816696" }, { "nct_id": "NCT04128293", "title": "A Relative Bioavailability and Food-Effect Study of GSK3640254 Tablet and Capsule Formulations in Healthy Participants", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "GSK3640254 Tablet", "type": "DRUG" }, { "name": "GSK3640254 Capsule", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 16, "start_date": "2019-10-08", "completion_date": "2019-11-15", "has_results": true, "last_update_posted_date": "2020-08-25", "last_synced_at": "2026-09-02T20:06:35.836Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04128293" }, { "nct_id": "NCT03784079", "title": "A Proof of Concept Study of GSK3640254 in Human Immunodeficiency Virus-1 (HIV-1) Infected Treatment-naive Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "GSK3640254", "type": "DRUG" }, { "name": "Placebo matching GSK3640254 Mesylate salt", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 34, "start_date": "2019-01-31", "completion_date": "2020-02-06", "has_results": true, "last_update_posted_date": "2021-02-16", "last_synced_at": "2026-09-02T20:06:35.836Z", "location_count": 2, "location_summary": "Bakersfield, California • Orlando, Florida", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03784079" }, { "nct_id": "NCT03984825", "title": "Effect of GSK3640254 on the Pharmacokinetics of a Combination Oral Contraceptive", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "GSK3640254", "type": "DRUG" }, { "name": "Portia", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "FEMALE", "summary": "18 Years to 50 Years · Female only" }, "enrollment_count": 23, "start_date": "2019-06-13", "completion_date": "2019-08-16", "has_results": true, "last_update_posted_date": "2020-08-27", "last_synced_at": "2026-09-02T20:06:35.836Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03984825" }, { "nct_id": "NCT03836729", "title": "Study to Evaluate the Effect of GSK3640254 on the Pharmacokinetics of Tenofovir Alafenamide/Emtricitabine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Tenofovir alafenamide/emtricitabine", "type": "DRUG" }, { "name": "GSK3640254", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 16, "start_date": "2019-02-11", "completion_date": "2019-04-30", "has_results": true, "last_update_posted_date": "2020-04-21", "last_synced_at": "2026-09-02T20:06:35.836Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03836729" }, { "nct_id": "NCT04263142", "title": "A Relative Bioavailability and Food-Effect Study of GSK3640254 Tablet and Capsule Formulations in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "GSK3640254 Tablet", "type": "DRUG" }, { "name": "GSK3640254 Capsule", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 39, "start_date": "2020-01-27", "completion_date": "2020-03-24", "has_results": true, "last_update_posted_date": "2021-03-03", "last_synced_at": "2026-09-02T20:06:35.836Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04263142" } ] }